Research Paper Volume 11, Issue 21 pp 9643—9660

Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling

Figure 7. USP22 overexpression positively correlates with advanced histological grade, metastasis, and poor prognosis in GC patients. (A) Representative images of IHC staining of USP22 and (B) USP22 expression scores in the sections of non-cancerous and GC tissues at various stages of differentiation. Scale bar: 10 μm. (C) USP22 expression scores in metastatic and non-metastatic GC tissue samples (n = 40). (D) Relationship between levels of USP22 expression based on IHC and the five-year overall survival (OS) rates after surgery in GC patients with high-USP22 (n = 107) and low-USP22 (n = 79) expression. Note: Data are expressed as mean ± SD of three replicates; *p < 0.05 compared with non-cancerous tissues or well-differentiated tissues in (B); *p < 0.05 compared with non-metastatic GC tissues in (C); #p < 0.05 compared with moderate-differentiated tissues in (B).